Stock Information

• Why Is Praxis Precision Stock Soaring Tuesday?
  Tue, Apr 14, 2026 2:02 PM
• Needham Reiterates Buy on Praxis Precision Medicine, Maintains $510 Price Target
  Tue, Apr 14, 2026 10:58 AM
• Praxis Precision Medicines Shares Rise After FDA Accepts New Drug Application
  Tue, Apr 14, 2026 10:48 AM
• Praxis Precision Medicines shares are trading higher after the company announced that the FDA accepted the review for its New Drug Application for ulixacaltamide HCl for the treatment of essential tremor in adults.
  Tue, Apr 14, 2026 9:27 AM
• Praxis Precision Medicines' New Drug Application For Ulixacaltamide HCI Receives FDA Acceptance For Review To Treat Essential Tremor
  Tue, Apr 14, 2026 7:34 AM
• Praxis Precision Medicines Announces FDA Acceptance of New Drug Application for Ulixacaltamide HCl in Patients with Essential Tremor
  Tue, Apr 14, 2026 7:31 AM
• Praxis To Present Expanded Analyses From The Phase 3 Essential3 Program Of Ulixacaltamide In Essential Tremor With New data From Its Advancing CNS Pipeline At The AAN Annual Meeting From April 18–22
  Mon, Apr 13, 2026 8:03 AM
• Praxis to Showcase Essential3, the First Positive Phase 3 Program in Essential Tremor, at AAN 2026
  Mon, Apr 13, 2026 8:01 AM

Financial data not available